[{"id":"4c345493-ab62-410a-b773-a42c655f0249","acronym":"PDC-LUNG-101","url":"https://clinicaltrials.gov/study/NCT03970746","created_at":"2021-01-18T19:31:48.798Z","updated_at":"2024-07-02T16:35:31.964Z","phase":"Phase 1/2","brief_title":"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC","source_id_and_acronym":"NCT03970746 - PDC-LUNG-101","lead_sponsor":"PDC*line Pharma SAS","biomarkers":" CD8 • HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["CD8 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pemetrexed • PDC*lung"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 09/10/2019","start_date":" 09/10/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-24"}]